Ticagrelor, a novel reversible P2Y12 receptor antagonist is more potent, more predictable and has a faster onset of action than Clopidogrel. It therefore gains more interest in modern cardiology and vascular medicine. Numerous ground breaking trials on Ticagrelor have been published in recent times which not only expands the indication to a larger population, but also challenges the need of DAPT making this drug a promising candidate for a first-choice antiplatelet agent in patients with acute coronary events. To discuss the recent developments on Ticagrelor, Access 360 and Docplexus have organized a webinar on 5th August 2020, Wednesday, 7:30 pm. In this webinar, Dr. Shireesh Sathe will be sharing his insights on the topic- Recent Updates On Ticagrelor.
Stay tuned! References: 1. Fundam Clin Pharmacol. 2012 Feb;26(1):16-8.doi: 10.1111/j.1472-8206.2011.00984.x. Epub 2011 Sep 5. 2.…
